Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 09, 2024

SELL
$26.43 - $32.77 $1,717 - $2,130
-65 Reduced 29.41%
156 $4,000
Q4 2023

Feb 12, 2024

BUY
$27.94 - $35.44 $4,358 - $5,528
156 Added 240.0%
221 $7,000
Q4 2022

Jan 24, 2023

BUY
$33.8 - $47.06 $2,197 - $3,058
65 New
65 $2.76 Million

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $15.2B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Rfp Financial Group LLC Portfolio

Follow Rfp Financial Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rfp Financial Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rfp Financial Group LLC with notifications on news.